Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yelena Shirman, Shlomit Lubovsky & Ayelet Shai. (2023) HER2-Low Breast Cancer: Current Landscape and Future Prospects. Breast Cancer: Targets and Therapy 15, pages 605-616.
Read now
Read now
Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione & Giuseppe Curigliano. (2022) Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opinion on Investigational Drugs 31:6, pages 499-513.
Read now
Read now
Paolo Tarantino, Stefania Morganti, Jacopo Uliano, Federica Giugliano, Edoardo Crimini & Giuseppe Curigliano. (2021) Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy 21:2, pages 127-133.
Read now
Read now
Articles from other publishers (19)
Wang Wang, Shujun Jiang, Yang Zhao & Guoxue Zhu. (2023) Echinacoside: A promising active natural products and pharmacological agents. Pharmacological Research 197, pages 106951.
Crossref
Crossref
Arya Mariam Roy, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal, Ruth O’Regan & Shipra Gandhi. (2023) A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer 129:18, pages 2773-2788.
Crossref
Crossref
Yichen Liu, Ying Chen, Qiong Zhao, Tianyuan Xie, Chenxi Xiang, Qianqian Guo, Wenzhou Zhang, Yi Zhou, Yin Yuan, Yuxin Zhang, Tao Xi, Xiaoman Li & Lufeng Zheng. (2023)
A positive TGF‐β/
miR‐9
regulatory loop promotes the expansion and activity of tumour‐initiating cells in breast cancer
. British Journal of Pharmacology 180:17, pages 2280-2297.
Crossref
Crossref
Marta Nerone, Lorenzo Rossi, Rosaria Condorelli, Vilma Ratti, Fabio Conforti, Antonella Palazzo & Rossella Graffeo. (2023) Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies. Cancers 15:13, pages 3305.
Crossref
Crossref
M. A. Kolganova, O. S. Sagimbaeva, Ju. S. Borisova, E. E. Beketov & I. E. Shokhin. (2023) Development and Validation of the ELISA Method for Neutralizing Anti-trastuzumab Antibodies Detection in Human Blood Serum. Drug development & registration 12:2, pages 190-197.
Crossref
Crossref
Ritu Rai. (2023) An Overview of Breast Cancer Epidemiology, Risk Factors, Classification, Genetics, Diagnosis and Treatment. Vantage 4:1, pages 45-67.
Crossref
Crossref
Vaishali Kilor, Vipin Dhote, Nidhi Sapkal & Shagufta Khan. 2023. Nanotechnology Principles in Drug Targeting and Diagnosis. Nanotechnology Principles in Drug Targeting and Diagnosis
145
172
.
Tomás Reinert, Fanny Cascelli, Cristiano Augusto Andrade de Resende, Aline Coelho Gonçalves, Vania Sanchez Prette Godo & Carlos Henrique Barrios. (2022) Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Frontiers in Endocrinology 13.
Crossref
Crossref
Francesco Bruno, Domenico Arcuri, Francesca Vozzo, Antonio Malvaso, Alberto Montesanto & Raffaele Maletta. (2022) Expression and Signaling Pathways of Nerve Growth Factor (NGF) and Pro-NGF in Breast Cancer: A Systematic Review. Current Oncology 29:11, pages 8103-8120.
Crossref
Crossref
Anna Wawruszak, Estera Okon, Ilona Telejko, Arkadiusz Czerwonka & Jarogniew Luszczki. (2022) Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells. Pharmacological Reports 74:5, pages 1011-1024.
Crossref
Crossref
Erika Plazas, Mónica C. Avila M, Diego R. Muñoz & Luis E. Cuca S. (2022) Natural isoquinoline alkaloids: Pharmacological features and multi-target potential for complex diseases. Pharmacological Research 177, pages 106126.
Crossref
Crossref
Sophie Day, Jayne Smith & Helen Ward. 2022. Figure. Figure
149
172
.
Md Abdus Subhan & Vladimir P. Torchilin. (2021) Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 169, pages 241-255.
Crossref
Crossref
Sugumari Vallinayagam, Karthikeyan Rajendran & Vigneshkumar Sekar. (2021) Green synthesis and characterization of silver nanoparticles using Naringi crenulate leaf extract: Key challenges for anticancer activities. Journal of Molecular Structure 1243, pages 130829.
Crossref
Crossref
Paolo Tarantino, Dario Trapani & Giuseppe Curigliano. (2021) Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncology Practice 17:10, pages 605-606.
Crossref
Crossref
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz & Andrzej Stanisławek. (2021) Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers 13:17, pages 4287.
Crossref
Crossref
Aotong Zhang, Xin Qi, Fu Du, Guojian Zhang, Dehai Li & Jing Li. (2021) PNSA, a Novel C-Terminal Inhibitor of HSP90, Reverses Epithelial–Mesenchymal Transition and Suppresses Metastasis of Breast Cancer Cells In Vitro. Marine Drugs 19:2, pages 117.
Crossref
Crossref
Sulaiman S. Alhudaithi, Rashed M. Almuqbil, Hanming Zhang, Elizabeth R. Bielski, Wei Du, Fatemah S. Sunbul, Paula D. Bos & Sandro R. P. da Rocha. (2020) Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases. Molecular Pharmaceutics 17:12, pages 4691-4703.
Crossref
Crossref
Paul T. Winnard, Farhad Vesuna, Sankar Muthukumar & Venu Raman. (2020) Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity. PLOS ONE 15:11, pages e0242384.
Crossref
Crossref